Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer

Journal of Controlled Release

Volumn 199, Issue , 2015, Pages 72-83

  Neijzen, Robert ^a,b   Wong, May Q ^b   Gill, Navdeep ^b   Wang, He ^b   Karim, Tamanna ^b   Anantha, Malathi ^b   Strutt, Dita ^b   Waterhouse, Dawn ^b   Bally, Marcel B ^b,c,d   Tai, Isabella T ^b,c   Ng, Sylvia S W ^b,c   Yapp, Donald T ^b,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Centre for Drug Research and Development   (Canada)

Author keywords

Colorectal cancer; HT 29 tumors; Irinotecan; Liposomes; Patient derived xenografts; Sequential therapy

Indexed keywords

BIOLOGICAL MATERIALS; CELL DEATH; DISEASES; ENDOTHELIAL CELLS; LIPOSOMES; MAMMALS; PATIENT TREATMENT; SCINTILLATION; TOXICITY;

COLORECTAL CANCER; IRINOTECAN; LIPOSOMAL FORMULATION; LIQUID SCINTILLATION; PATIENT DERIVED XENOGRAFTS; SEQUENTIAL THERAPY; VASCULAR NORMALIZATION; VASCULAR STRUCTURES;

TUMORS;

FIRTECAN; FLUOROURACIL; HOE 33342; IRINOTECAN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; NANOMATERIAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD VESSEL FUNCTION; CELL COUNT; CELL DENSITY; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENDOTHELIUM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIQUID SCINTILLATION COUNTING; MOUSE; NONHUMAN; SCINTILLATION; SINGLE DRUG DOSE; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD FLOW; BLOOD VESSEL; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; HT 29 CELL LINE; MEDICINAL CHEMISTRY; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD VESSELS; CAMPTOTHECIN; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; COLONIC NEOPLASMS; DRUG DELIVERY SYSTEMS; FLUOROURACIL; HT29 CELLS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NANOSTRUCTURES; REGIONAL BLOOD FLOW; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918795218     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.11.031     Document Type: Article

References (32)

1. B.M. Wolpin, and R.J. Mayer Systemic treatment of colorectal cancer Gastroenterology 134 5 2008 1296 1310 (Epub 2008/05/13)
2. R. Midgley, and D. Kerr Bevacizumab - current status and future directions Ann. Oncol. 16 7 2005 999 1004
3. C. Eng Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer Nat. Rev. Clin. Oncol. 6 4 2009 207 218 (Epub 2009/04/01)
4. C. Jackson, and D. Cunningham Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer Eur. J. Cancer 44 5 2008 652 662 (Epub 2008/03/04)
5. B.W. Kang, T.W. Kim, J.L. Lee, M.H. Ryu, H.M. Chang, and C.S. Yu Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis Med. Oncol. 26 1 2009 32 37 (Epub 2008/5/22)
6. C.J. Punt, and J. Tol More is less - combining targeted therapies in metastatic colorectal cancer Nat. Rev. Clin. Oncol. 6 12 2009 731 733 (Epub 2009/11/28)
7. Y. Kawato, M. Aonuma, Y. Hirota, H. Kuga, and K. Sato Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11 Cancer Res. 51 16 1991 4187 4191 (Epub 1991/08/15)
8. F. Lavelle, M.C. Bissery, S. Andre, F. Roquet, and J.F. Riou Preclinical evaluation of CPT-11 and its active metabolite SN-38 Semin. Oncol. 23 1 Suppl. 3 1996 11 20 (Epub 1996/02/01)
9. R.H. Mathijssen, R.J. van Alphen, J. Verweij, W.J. Loos, K. Nooter, and G. Stoter Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clin. Cancer Res. 7 8 2001 2182 2194 (Epub 2001/08/08)
10. L.P. Rivory, E. Chatelut, P. Canal, A. Mathieu-Boue, and J. Robert Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients Cancer Res. 54 24 1994 6330 6333 (Epub 1994/12/15)
11. R. Khanna, C.L. Morton, M.K. Danks, and P.M. Potter Proficient metabolism of irinotecan by a human intestinal carboxylesterase Cancer Res. 60 17 2000 4725 4728 (Epub 2000/09/15)
12. S. Guichard, C. Terret, I. Hennebelle, I. Lochon, P. Chevreau, and E. Fretigny CPT-11 converting carboxylesterase and topoisomerase activities in tumor and normal colon and liver tissues Br. J. Cancer 80 3-4 1999 364 370 (Epub 1999/07/17)
13. F. Saliba, R. Hagipantelli, J.L. Misset, G. Bastian, G. Vassal, and M. Bonnay Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment J. Clin. Oncol. 16 8 1998 2745 2751 (Epub 1998/08/15)
14. L.R. Wiseman, A. Markham, and Irinotecan A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer Drugs 52 4 1996 606 623 (Epub 1996/10/01)
15. C.L. Messerer, E.C. Ramsay, D. Waterhouse, R. Ng, E.M. Simms, and N. Harasym Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer Clin. Cancer Res. 10 19 2004 6638 6649
16. E. Ramsay, J. Alnajim, M. Anantha, A. Taggar, A. Thomas, and K. Edwards Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation Pharm. Res. 23 12 2006 2799 2808
17. E. Ramsay, J. Alnajim, M. Anantha, J. Zastre, H. Yan, and M. Webb A novel liposomal irinotecan formulation with significant anti-tumor activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention Eur. J. Pharm. Biopharm. 68 3 2008 607 617
18. E.C. Ramsay, M. Anantha, J. Zastre, M. Meijs, J. Zonderhuis, and D. Strutt Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors Clin. Cancer Res. 14 4 2008 1208 1217
19. J.H. Baker, J. Lam, A.H. Kyle, J. Sy, T. Oliver, and S.J. Co Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin Clin. Cancer Res. 14 22 2008 7260 7271 (Epub 2008/11/18)
20. M. Verreault, D. Strutt, D. Masin, M. Anantha, D. Waterhouse, and D.T. Yapp Irinophore C, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model J. Controlled Release 158 1 2012 34 43 (Epub 2011/10/18)
21. M. Verreault, D. Strutt, D. Masin, M. Anantha, A. Yung, and P. Kozlowski Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C), doxorubicin (Caelyx(R)) or vincristine BMC Cancer 11 2011 124 (Epub 2011/04/12)
22. J.I. Hare, R.W. Neijzen, M. Anantha, N. Dos Santos, N. Harasym, and M.S. Webb Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C) and 5-fluorouracil PLoS One 8 4 2013 e62349 (Epub 2013/04/30)
23. J.H. Baker, L.A. Huxham, A.H. Kyle, K.K. Lam, and A.I. Minchinton Vascular-specific quantification in an in vivo Matrigel chamber angiogenesis assay Microvasc. Res. 71 2 2006 69 75 (Epub 2006/03/21)
24. J. Low, S. Huang, W. Blosser, M. Dowless, J. Burch, and B. Neubauer High-content imaging characterization of cell cycle therapeutics through in vitro and in vivo subpopulation analysis Mol. Cancer Ther. 7 8 2008 2455 2463 (Epub 2008/08/30)
25. G. Bocci, K.C. Nicolaou, and R.S. Kerbel Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs Cancer Res. 62 23 2002 6938 6943
26. P. Carmeliet, and R.K. Jain Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases Nat. Rev. Drug Discov. 10 6 2011 417 427 (Epub 2011/06/02)
27. S. Goel, D.G. Duda, L. Xu, L.L. Munn, Y. Boucher, and D. Fukumura Normalization of the vasculature for treatment of cancer and other diseases Physiol. Rev. 91 3 2011 1071 1121 (Epub 2011/07/12)
28. R.G. Azrak, S. Cao, H.K. Slocum, K. Toth, F.A. Durrani, and M.B. Yin Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts Clin. Cancer Res. 10 3 2004 1121 1129 (Epub 2004/02/12)
29. S. Mullany, P.A. Svingen, S.H. Kaufmann, and C. Erlichman Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity Cancer Chemother. Pharmacol. 42 5 1998 391 399 (Epub 1998/10/15)
30. S. Guichard, I. Hennebelle, R. Bugat, and P. Canal Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line Biochem. Pharmacol. 55 5 1998 667 676 (Epub 1998/03/27)
31. D.R. Mans, I. Grivicich, G.J. Peters, and G. Schwartsmann Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines Eur. J. Cancer 35 13 1999 1851 1861 (Epub 2000/02/16)
32. Meta-analysis Group In Cancer Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer J. Clin. Oncol. 16 1 1998 301 308 (Epub 1998/01/24)